Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.

Abstract

Immune checkpoint inhibitors-based immunotherapy offers a new effective modality in the treatment of advanced malignancies. Considering the remarkable efficacy of immune checkpoint inhibitors in clinical trials, the FDA has approved a variety of immune checkpoint inhibitors for the treatment of advanced tumors. However, only limited patients with certain cancers can benefit from monotherapy of immune checkpoint inhibitors. Interventional therapy for cancer can not only destroy the primary tumors, but also regulate the immune system through different mechanisms, which provides a potential possibility for the combination of immune checkpoint inhibitors and interventional modalities in cancer treatment. This article reviews the possible synergistic mechanisms of interventional therapy combined with immune checkpoint inhibitors and summarizes the research progress of the combined therapy in cancer treatment.

• Authors: Xiaofeng Chang, Xiaofeng Lu, Jinhe Guo, Gao-Jun Teng
• Journal: Cancer treatment reviews (Cancer Treat Rev) Vol. 74 Pg. 49-60 (Mar 2019) ISSN: 1532-1967 [Electronic] Netherlands
• PMID: 30831375 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2018. Published by Elsevier Ltd.

Chemical References

• Antineoplastic Agents, Immunological
• B7-H1 Antigen
• CD274 protein, human
• CTLA-4 Antigen
• CTLA4 protein, human
• PDCD1 protein, human
• PDCD1LG2 protein, human
• Programmed Cell Death 1 Ligand 2 Protein
• Programmed Cell Death 1 Receptor

Topics

• Ablation Techniques
• Animals
• Antineoplastic Agents, Immunological (therapeutic use)
• B7-H1 Antigen (antagonists & inhibitors, immunology)
• Brachytherapy
• CTLA-4 Antigen (antagonists & inhibitors, immunology)
• Chemoembolization, Therapeutic
• Humans
• Immunotherapy (methods)
• Neoplasms (drug therapy, immunology, therapy)
• Programmed Cell Death 1 Ligand 2 Protein (antagonists & inhibitors, immunology)
• Programmed Cell Death 1 Receptor (antagonists & inhibitors, immunology)